Next Generation Glioma Treatments using Direct Light Therapy (GlioLighT)

使用直接光疗法 (GlioLighT) 的下一代神经胶质瘤治疗

• 批准号: 10110169
• 金额: $ 17.33万
• 依托单位: MODUS RESEARCH AND INNOVATION LIMITED
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10110169
• 关键词: Next; Generation; Glioma; Treatments; using

Glioma is an extremely lethal cancer, due largely to the inaccessible nature of the brain and diffusion of cells from the tumour site. These diffuse cells are usually too deeply embedded in the brain to safely remove by current means. Targeted Reactive Oxygen Species (ROS) generation is a promising form of glioma treatment to selectively eliminate glioma, including diffuse cells. However, the only current means of targeted ROS generation is photodynamic therapy (PDT) which generates ROS using expensive and potentially toxic photosensitisers (PS) which are ineffective against distant diffused cells and introduce many treatment limitations. GlioLighT proposes a novel alternative form of targeted ROS generation: Direct Light Therapy (DLT). DLT uses 1267nm light to generate 1O2 species in glioma cells without dependency on a PS. The removal of PS will revolutionise glioma treatment, enabling novel treatment modalities to vastly improve efficacy, earlier intervention options, all at reduced cost and complexity. However, whilst the principles of DLT have been demonstrated, little is known about how DLT achieves its anti-cancer effects, or the extent of its therapeutic benefits. Leveraging decades of accumulated PDT knowledge and technology development, GlioLighT will study DLT technology both independently and compared to PDT. The effect of DLT on glioma and the brain, focusing on immunogenicity, will be studied to determine DLT’s efficacy, safety, and mechanisms of action. Novel ultrashort pulse (USP) light sources will be developed to maximise optical penetration and minimise safety risk, ensuring DLT is suited for clinical adoption. Lastly, the development of the preclinical GlioLighT delivery and sensing system (pcGlio-DSS) ready for the next steps of clinical translation, will bring DLT a leap closer to vastly improving glioma treatment in Europe and worldwide.

神经胶质瘤是一种极其致命的癌症，主要是由于难以接近大脑以及肿瘤部位细胞的扩散，这些扩散的细胞通常嵌入大脑太深，无法通过当前的手段安全地去除。 ROS 产生是一种有前途的神经胶质瘤治疗形式，可选择性消除神经胶质瘤，包括弥漫性细胞。然而，目前唯一产生靶向 ROS 的方法是光动力疗法 (PDT)，它使用昂贵且具有潜在毒性的光敏剂产生 ROS。 GlioLighT 提出了一种新型的靶向 ROS 生成替代形式：直接光疗法 (DLT)，使用 1267nm 光在神经胶质瘤细胞中产生 1O2 物质，而不依赖于 PS。 PS 的去除将彻底改变神经胶质瘤的治疗，使新的治疗方式能够大大提高疗效、早期干预选择，同时降低成本和复杂性。事实证明，人们对 DLT 如何实现其抗癌作用或其治疗益处的程度知之甚少，GlioLighT 将利用数十年积累的 PDT 知识和技术发展来独立研究 DLT 技术并与 DLT 的效果进行比较。将研究胶质瘤和大脑，重点关注免疫原性，以确定 DLT 的功效、安全性和作用机制，并将开发新型超短脉冲 (USP) 光源，以最大限度地提高光学穿透性并最大限度地降低安全性。最后，临床前 GlioLighT 传输和传感系统 (pcGlio-DSS) 的开发为下一步的临床转化做好了准备，将使 DLT 更接近于大幅改善欧洲和欧洲的神经胶质瘤治疗。全世界。